MCID: NRL004
MIFTS: 44

Neuroleptic Malignant Syndrome

Categories: Rare diseases, Neuronal diseases

Aliases & Classifications for Neuroleptic Malignant Syndrome

MalaCards integrated aliases for Neuroleptic Malignant Syndrome:

Name: Neuroleptic Malignant Syndrome 12 72 49 50 55 36 51 41 14 69

Characteristics:

Orphanet epidemiological data:

55
neuroleptic malignant syndrome
Prevalence: 1-5/10000 (Europe);

Classifications:

Orphanet: 55  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:14464
ICD10 32 G21.0
ICD9CM 34 333.92
MeSH 41 D009459
NCIt 46 C94829
Orphanet 55 ORPHA94093
MESH via Orphanet 42 D009459
UMLS via Orphanet 70 C0027849
ICD10 via Orphanet 33 G21.0
KEGG 36 H01528
UMLS 69 C0027849

Summaries for Neuroleptic Malignant Syndrome

NIH Rare Diseases : 49 Neuroleptic malignant syndrome is a rare neurological condition that is caused by an adverse reaction to neuroleptic (tranquilizer) or antipsychotic drugs. These drugs are commonly prescribed for the treatment of schizophrenia and other neurological, mental, or emotional disorders. Affected people may experience high fever, muscle stiffness, sweating, unstable blood pressure, altered mental status, and autonomic dysfunction. In most cases, the condition develops within the first 2 weeks of treatment with the drug; however, it may develop any time during the therapy period. The exact underlying cause of neuroleptic malignant syndrome is unknown. In some cases, more than one family member can be affected which suggests there may be a genetic component. Upon diagnosis of the condition, the neuroleptic or antipsychotic drug is generally discontinued under a physician's supervision. Medications and/or other interventions may also be recommended to manage symptoms. Last updated: 7/14/2015

MalaCards based summary : Neuroleptic Malignant Syndrome is related to serotonin syndrome and myoglobinuria. An important gene associated with Neuroleptic Malignant Syndrome is PIK3C2A (Phosphatidylinositol-4-Phosphate 3-Kinase Catalytic Subunit Type 2 Alpha). The drugs Dopamine and Methylphenidate have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and brain, and related phenotypes are behavior/neurological and homeostasis/metabolism

NINDS : 50 Neuroleptic malignant syndrome is a life-threatening, neurological disorder most often caused by an adverse reaction to neuroleptic or antipsychotic drugs. Symptoms include high fever, sweating, unstable blood pressure, stupor, muscular rigidity, and autonomic dysfunction. In most cases, the disorder develops within the first 2 weeks of treatment with the drug; however, the disorder may develop any time during the therapy period. The syndrome can also occur in people taking anti-Parkinsonism drugs known as dopaminergics if those drugs are discontinued abruptly.

Disease Ontology : 12 A nervous system disease that is characterized by hyperthermia, muscular rigidity, autonomic dysfunction and altered consciousness and is associated with administration of antipsychotic and other central dopaminergic blockers.

Wikipedia : 72 Neuroleptic malignant syndrome (NMS) is a life-threatening reaction that occasionally occurs in response... more...

Related Diseases for Neuroleptic Malignant Syndrome

Diseases related to Neuroleptic Malignant Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 145)
# Related Disease Score Top Affiliating Genes
1 serotonin syndrome 30.6 CYP2D6 HTR1A
2 myoglobinuria 29.9 MB PIK3C2A
3 disseminated intravascular coagulation 29.8 MB PIK3C2A
4 generalized anxiety disorder 29.5 DRD2 HTR1A
5 metabolic encephalomyopathic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration 29.4 CHKB MB PIK3C2A RYR1
6 malignant hyperthermia 29.2 CHKB MB PIK3C2A RYR1
7 acute myocardial infarction 29.1 CHKB MB PIK3C2A
8 parkinson disease, late-onset 29.0 CYP2D6 DRD2 HTR1A
9 virus associated hemophagocytic syndrome 10.3 MB PIK3C2A
10 interstitial myocarditis 10.3 MB PIK3C2A
11 posterior myocardial infarction 10.3 MB PIK3C2A
12 myositis fibrosa 10.3 MB PIK3C2A
13 anuria 10.3 MB PIK3C2A
14 plexopathy 10.3 MB PIK3C2A
15 galactorrhea 10.3 CYP2D6 DRD2
16 intermediate coronary syndrome 10.3 MB PIK3C2A
17 tardive dyskinesia 10.3 CYP2D6 DRD2
18 acute mountain sickness 10.3 MB PIK3C2A
19 pseudohyperkalemia, familial, 2, due to red cell leak 10.3 MB PIK3C2A
20 muscle disorders 10.2 PIK3C2A RYR1
21 acute kidney failure 10.2 MB PIK3C2A
22 encephalitis 10.2
23 gastroparesis 10.2 CYP2D6 DRD2
24 dementia 10.1
25 cerebritis 10.1
26 periodic limb movement disorder 10.1 DRD2 HTR1A
27 alexithymia 10.1 DRD2 HTR1A
28 schizophrenia 10.1
29 drug-induced mental disorder 10.0 DRD2 HTR1A
30 drug psychosis 10.0 DRD2 HTR1A
31 mental depression 10.0 CYP2D6 HTR1A
32 substance abuse 10.0 CYP2D6 DRD2
33 migraine without aura 10.0 DRD2 HTR1A
34 brain injury 10.0
35 encephalopathy 10.0
36 muscle tissue disease 10.0 MB PIK3C2A RYR1
37 hypersomnia 9.9 CHKB CYP2D6
38 bipolar disorder 9.9
39 burns 9.9
40 cerebral palsy 9.9
41 traumatic brain injury 9.9
42 status epilepticus 9.9
43 dystonia 9.9
44 cerebellar degeneration 9.9
45 pericardial effusion 9.9 CHKB PIK3C2A
46 substance dependence 9.9 CYP2D6 DRD2
47 personality disorder 9.9 DRD2 HTR1A
48 systemic lupus erythematosus 9.9
49 myocardial infarction 9.9
50 diabetes mellitus, ketosis-prone 9.9

Graphical network of the top 20 diseases related to Neuroleptic Malignant Syndrome:



Diseases related to Neuroleptic Malignant Syndrome

Symptoms & Phenotypes for Neuroleptic Malignant Syndrome

MGI Mouse Phenotypes related to Neuroleptic Malignant Syndrome:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.63 CHKB DRD2 HTR1A NHLRC1 PIK3C2A RYR1
2 homeostasis/metabolism MP:0005376 9.5 CHKB DRD2 HTR1A MB NHLRC1 PIK3C2A
3 muscle MP:0005369 9.02 CHKB DRD2 MB NHLRC1 RYR1

Drugs & Therapeutics for Neuroleptic Malignant Syndrome

Drugs for Neuroleptic Malignant Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 78)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
2
Methylphenidate Approved, Investigational Phase 4 20748-11-2, 113-45-1 4158
3 Central Nervous System Stimulants Phase 4
4 Dopamine Agents Phase 4,Phase 3,Phase 2
5 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
6 Dopamine Uptake Inhibitors Phase 4
7 Neurotransmitter Uptake Inhibitors Phase 4
8
Haloperidol Approved Phase 3,Phase 2 52-86-8 3559
9
Carbidopa Approved Phase 3 28860-95-9 38101 34359
10
Levodopa Approved Phase 3 59-92-7 6047
11
Ziprasidone Approved Phase 3 146939-27-7 60854
12 Antipsychotic Agents Phase 3,Phase 2
13 Antiemetics Phase 3,Phase 2
14 Autonomic Agents Phase 3,Phase 2
15 Central Nervous System Depressants Phase 3,Phase 2
16 decanoic acid Phase 3,Phase 2
17 Dopamine Antagonists Phase 3,Phase 2
18 Gastrointestinal Agents Phase 3,Phase 2
19 Haloperidol decanoate Phase 3,Phase 2
20 Peripheral Nervous System Agents Phase 3,Phase 2
21 Psychotropic Drugs Phase 3,Phase 2
22 Quetiapine Fumarate Phase 3 111974-72-2
23 Tranquilizing Agents Phase 3,Phase 2
24 Dopamine agonists Phase 3
25 Adjuvants, Immunologic Phase 3
26 Antiparkinson Agents Phase 3
27 Aromatic Amino Acid Decarboxylase Inhibitors Phase 3
28 Carbidopa, levodopa drug combination Phase 3
29
Serotonin Phase 3 50-67-9 5202
30 Serotonin Agents Phase 3
31 Serotonin Antagonists Phase 3
32
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
33
Lenvatinib Approved, Investigational Phase 2 417716-92-8
34
Ketamine Approved, Vet_approved Phase 2 6740-88-1 3821
35
Midazolam Approved, Illicit Phase 2 59467-70-8 4192
36 Protein Kinase Inhibitors Phase 2
37 Anesthetics Phase 2
38 Adjuvants, Anesthesia Phase 2
39 Analgesics Phase 2
40 Anesthetics, Dissociative Phase 2
41 Anesthetics, General Phase 2
42 Anesthetics, Intravenous Phase 2
43 Anti-Anxiety Agents Phase 2
44 Excitatory Amino Acid Antagonists Phase 2
45 Excitatory Amino Acids Phase 2
46 GABA Agents Phase 2
47 GABA Modulators Phase 2
48 Hypnotics and Sedatives Phase 2
49 Antibodies Phase 1
50 Immunoglobulins Phase 1

Interventional clinical trials:

(show all 40)

# Name Status NCT ID Phase Drugs
1 The Effect of Methylphenidate on Non-motor Symptoms and Postural Control in Parkinson's Disease. Terminated NCT01244269 Phase 4 Methylphenidate;Methylphenidate;Placebo 10;Placebo 20
2 Trial Comparing Haloperidol, Quetiapine and Placebo in the Pharmacological Treatment of Delirium Completed NCT01811459 Phase 3 Quetiapine;Haloperidol;Placebo
3 A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD) Recruiting NCT02549092 Phase 3 ABT-SLV187
4 The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study Recruiting NCT01211522 Phase 3 Haloperidol;Ziprasidone;Placebo
5 Mindfulness Based Intervention (MBI) on the Quality of Life and Non-Motor Symptoms (NMS) of Persons With PD Completed NCT01607697 Phase 2
6 Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of Schizophrenia Completed NCT01176721 Phase 2
7 Nucleus Basalis Deep Brain Stimulation for Thinking & Memory Problems in Parkinson's. Completed NCT01701544 Phase 1, Phase 2
8 Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial Recruiting NCT01627132 Phase 2 Dasatinib
9 Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer Recruiting NCT02726503 Phase 2 Lenvatinib
10 Rapid Agitation Control With Ketamine in the Emergency Department Not yet recruiting NCT03375671 Phase 2 Ketalar;Midazolam injection;Haloperidol
11 Study of NMS-1286937 in Adult Patients With Advanced/Metastatic Solid Tumors Completed NCT01014429 Phase 1 NMS-1286937
12 Safety of RG2077 in Patients With Multiple Sclerosis Completed NCT00076934 Phase 1 RG2077 (CTLA4-IgG4m)
13 Reducing Orthostatic Intolerance With Oral Rehydration in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients Recruiting NCT02854683 Phase 1 Normal Saline
14 Recovery of Physical Functioning After Hip Fracture Not yet recruiting NCT02780076 Phase 1
15 Study of NMS-1116354 in Solid Tumors Terminated NCT01016327 Phase 1 NMS-1116354
16 Study of NMS-1116354 in Advanced/Metastatic Solid Tumors Terminated NCT01092052 Phase 1 NMS-1116354
17 Occipital Nerve Stimulation in the Treatment of Migraine Terminated NCT01855672 Phase 1
18 The Iliac Arterio-venous Fistula for Treatment of Neurally Mediated Syncope Study Unknown status NCT02388087
19 Study of the Causes of the Breakdown of Muscle Fibers in Hospitalized Patients Unknown status NCT01022450
20 Understanding and Appraising the New Medicine Service in England Completed NCT01635361
21 Non-interventional, Retrospective, Multi-center Study to Evaluate Non-motor Symptoms in Advanced Parkinson Disease (PD) Patients Already Treated With Rotigotine Completed NCT01504529
22 Help-seeking for Health Problems in People With Parkinson's Completed NCT03275649
23 A Feasibility Study of the Impact on Blood Pressure Control of Supplementing Community Pharmacist Services With Structured Information on Blood Pressure and Its Treatment Completed NCT01939860
24 Distribution of Non-Motor Symptoms in Idiopathic Parkinson's Disease and Secondary Parkinsonism Completed NCT03432338
25 Long Time Follow up After HJ Following Iatrogenic Bile Duct Injuries Completed NCT01447030
26 rTMS Effects on Smoking Cessation and Cognition in Schizophrenia Completed NCT00736710
27 Deep TMS for the Treatment of Patients With Parkinson's Disease and Progressive Supranuclear Palsy Completed NCT02734485
28 Neuromuscular Electrostimulation in Radiocephalic Fistula Recruiting NCT02925845
29 Role of Deep Brain Stimulation on Social Cognition in Parkinsonian Patients Recruiting NCT03004573
30 Activity Dependent Rehabilitation Model to Improve Bone and Muscle Outcomes Recruiting NCT02309983
31 Intestinal Colonization in Newborn Infants With Enterostomy Recruiting NCT03340259
32 Effects of TENS and IES on the Autonomous Balance of Normotens Volunteers and Hypertensive Patients Recruiting NCT03258489
33 Incidence of Residual Neuromuscular Blockade in Intra-abdominal Surgery: A Prospective, Observational Study Active, not recruiting NCT02984839
34 Incidence of Postoperative Neuromuscular Blockade in Post-Anesthesia Care Unit at Parkland Hospital: Does Size Matter? Active, not recruiting NCT03111082
35 The Effect of Parkinson Kinetigraph Recordings on the Management and Outcome in Parkinson's Disease Enrolling by invitation NCT03152721
36 Studying Non-motor Symptoms in SPG4 Not yet recruiting NCT03204773
37 Medical and Economic Evaluation of a Magnetic Anal Sphincter for Patients With Severe Anal Incontinence Suspended NCT01920607
38 Clonidine for Neonatal Abstinence Syndrome Study Terminated NCT01175668 Clonidine;Phenobarbital
39 The Response Patterns to the Electrical Stimulation of Epidural Catheters With Varying Pulse Widths in Term Pregnant Women Terminated NCT02762149
40 Effects of Fish or Meat Consumption in Elderly Terminated NCT02045355

Search NIH Clinical Center for Neuroleptic Malignant Syndrome

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: neuroleptic malignant syndrome

Genetic Tests for Neuroleptic Malignant Syndrome

Anatomical Context for Neuroleptic Malignant Syndrome

MalaCards organs/tissues related to Neuroleptic Malignant Syndrome:

38
Kidney, Heart, Brain, Liver, Thyroid, Myeloid, Bone

Publications for Neuroleptic Malignant Syndrome

Articles related to Neuroleptic Malignant Syndrome:

(show top 50) (show all 662)
# Title Authors Year
1
Neuroleptic Malignant Syndrome: Diagnosis and Management. ( 29325237 )
2018
2
Neuroleptic malignant syndrome in pregnancy: case report and literature review. ( 29363376 )
2018
3
Neuroleptic malignant syndrome: a case responding to electroconvulsive therapy plus bupropion. ( 29441189 )
2018
4
Neuroleptic malignant syndrome as a presenting feature of subacute sclerosing panencephalitis. ( 29243130 )
2018
5
Neuroleptic Malignant Syndrome After Early Administration of Risperidone Long-Acting Injection. ( 29195036 )
2017
6
Neuroleptic malignant syndrome following catatonia: Vigilance is the price of antipsychotic prescription. ( 28491312 )
2017
7
Olanzapine induced neuroleptic malignant syndrome, treated with electroconvulsive therapy (ECT)-A case report. ( 28736031 )
2017
8
Neuroleptic malignant syndrome in a patient with stable dose of olanzapine. ( 29026773 )
2017
9
Bitemporal ultra-brief pulse electroconvulsive therapy for the treatment of neuroleptic malignant syndrome in a first psychotic episode: a case report. ( 28403325 )
2017
10
Neuroleptic Malignant Syndrome Following Bilateral Cemented Total Hip Replacements. ( 29151017 )
2017
11
Acute Dystonia Versus Neuroleptic Malignant Syndrome Without Fever in an Eight-Year-Old Child. ( 28045840 )
2017
12
Neuroleptic malignant syndrome following quetiapine treatment in a patient with dementia with Lewy bodies. ( 29080512 )
2017
13
Neuroleptic malignant syndrome (NMS) associated with amisulpride and sertraline use: A case report and discussion. ( 29174670 )
2017
14
Neuroleptic Malignant Syndrome/Malignant Catatonia in Child Psychiatry: Literature Review and a Case Series. ( 28398818 )
2017
15
Clozapine withdrawal catatonia, psychosis and associated neuroleptic malignant syndrome. ( 28846884 )
2017
16
Pharmacist intervention to detect drug adverse events on admission to the emergency department: Two case reports of neuroleptic malignant syndrome. ( 28488314 )
2017
17
A Validation Study of the International Consensus Diagnostic Criteria for Neuroleptic Malignant Syndrome. ( 28027111 )
2017
18
Olanzapine-induced Neuroleptic Malignant Syndrome. ( 28615778 )
2017
19
Oral Asenapine overdose leading to Neuroleptic Malignant Syndrome (NMS). ( 28711682 )
2017
20
Neuroleptic malignant syndrome in the trauma intensive care unit: Diagnosis and management of a rare disease in a challenging population. ( 28660166 )
2017
21
Atypical neuroleptic malignant syndrome (NMS). ( 28892745 )
2017
22
Drug information update. Atypical antipsychotics and neuroleptic malignant syndrome: nuances and pragmatics of the association. ( 28811916 )
2017
23
A Case of "Brief" Aripiprazole-induced Neuroleptic Malignant Syndrome with Symptoms that Only Lasted a Few Hours. ( 28943586 )
2017
24
Risperidone-Associated Rhabdomyolysis Without Neuroleptic Malignant Syndrome: A Case Report. ( 27861195 )
2017
25
Neuroleptic malignant syndrome with thyroid disorder: An unusual case report. ( 28953679 )
2017
26
Aripiprazole-induced neuroleptic malignant syndrome. ( 28558896 )
2017
27
Confusing Terminology-Neuroleptic Malignant Syndrome vs Malignant Hyperthermia-Reply. ( 28558105 )
2017
28
Anti-N-Methyl-D-Aspartate Receptor Encephalitis and Risk of Neuroleptic Malignant Syndrome. ( 27836566 )
2017
29
Lurasidone-Associated Neuroleptic Malignant Syndrome. ( 28806387 )
2017
30
Atypical Neuroleptic Malignant Syndrome: Diagnosis and Proposal for an Expanded Treatment Algorithm: A Case Report. ( 28767476 )
2017
31
Olanzapine-Induced Neuroleptic Malignant Syndrome. ( 28533580 )
2017
32
Progressive Encephalomyelitis with Rigidity and Myoclonus in an Intellectually Disabled Patient Mimicking Neuroleptic Malignant Syndrome. ( 28352055 )
2017
33
Early introduction of clozapine after neuroleptic malignant syndrome may prevent malignant catatonia: A case report. ( 27939254 )
2017
34
Neuroleptic malignant syndrome: A neuro-psychiatric emergency: Recognition, prevention, and management. ( 29061403 )
2017
35
Managing Manic Delirium in Bipolar Disorder With Features of Mania, Catatonia, and Neuroleptic Malignant Syndrome. ( 29272572 )
2017
36
Neuroleptic malignant syndrome associated with only one dose of metoclopramide in an older adult. ( 28849625 )
2017
37
Confusing Terminology-Neuroleptic Malignant Syndrome vs Malignant Hyperthermia. ( 28558090 )
2017
38
Reversible splenial lesion syndrome with a hyperosmolar hyperglycemic state and neuroleptic malignant syndrome caused by olanzapine. ( 27863115 )
2016
39
Overlapping of Serotonin Syndrome with Neuroleptic Malignant Syndrome due to Linezolid-Fluoxetine and Olanzapine-Metoclopramide Interactions: A Case Report of Two Serious Adverse Drug Effects Caused by Medication Reconciliation Failure on Hospital Admission. ( 27433163 )
2016
40
Atypical Neuroleptic Malignant Syndrome Associated With Paliperidone Long-Acting Injection: A Case Report. ( 27043124 )
2016
41
Anti-N-Methyl-D-Aspartate Receptor Encephalitis: A Potential Mimic of Neuroleptic Malignant Syndrome. ( 27590992 )
2016
42
Clinically mild encephalopathy with a reversible splenial lesion and nonconvulsive status epilepticus in a schizophrenic patient with neuroleptic malignant syndrome. ( 27976828 )
2016
43
Neuroleptic malignant syndrome. ( 27453870 )
2016
44
Neuroleptic Malignant Syndrome Associated with Refractory Acute Disseminated Encephalomyelitis. ( 27239186 )
2016
45
Catatonic Symptoms Appearing before Autonomic Symptoms Help Distinguish Neuroleptic Malignant Syndrome from Malignant Catatonia. ( 27725556 )
2016
46
Atypical neuroleptic malignant syndrome. ( 27298291 )
2016
47
Olanzapine Long-Acting Injections After Neuroleptic Malignant Syndrome: Two Case Reports. ( 27626284 )
2016
48
Venous Thromboembolism Following Dantrolene Treatment for Neuroleptic Malignant Syndrome. ( 27776396 )
2016
49
Management of Serotonin Syndrome and Neuroleptic Malignant Syndrome. ( 27469512 )
2016
50
Rocuronium-sugammadex for electroconvulsive therapy management in neuroleptic malignant syndrome: A case report. ( 27424873 )
2016

Variations for Neuroleptic Malignant Syndrome

Expression for Neuroleptic Malignant Syndrome

Search GEO for disease gene expression data for Neuroleptic Malignant Syndrome.

Pathways for Neuroleptic Malignant Syndrome

GO Terms for Neuroleptic Malignant Syndrome

Biological processes related to Neuroleptic Malignant Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 release of sequestered calcium ion into cytosol GO:0051209 8.96 DRD2 RYR1
2 response to hypoxia GO:0001666 8.8 DRD2 MB RYR1

Molecular functions related to Neuroleptic Malignant Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 drug binding GO:0008144 8.96 CYP2D6 DRD2
2 oxygen binding GO:0019825 8.62 CYP2D6 MB

Sources for Neuroleptic Malignant Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....